Stonebridge Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Stonebridge Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-8,950	Closed	-$239K	–	117
2019 Q2	$239K	Buy	8,950 +350	+4%	+$8.94K	0.09%	114
2019 Q1	$231K	Sell	8,600 -5,605	-39%	-$131K	0.08%	122
2018 Q4	$230K	Buy	14,205 +1,775	+14%	+$34.5K	0.09%	115
2018 Q3	$258K	Sell	12,430 -400	-3%	-$6.29K	0.09%	110
2018 Q2	$213K	Buy	+12,830	New	+$229K	0.08%	118
2016 Q2	–	Sell	-24,110	Closed	-$675K	–	131
2016 Q1	$675K	Buy	24,110 +14,720	+157%	+$321K	0.29%	59
2015 Q4	$334K	Buy	+9,390	New	+$331K	0.14%	120
2015 Q3	–	Sell	-6,930	Closed	-$290K	–	160
2015 Q2	$290K	Hold	6,930	–	–	0.12%	131
2015 Q1	$226K	Hold	6,930	–	–	0.09%	148
2014 Q4	$220K	Buy	+6,930	New	+$197K	0.08%	162

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Stonebridge Capital Management's ACAD Position: Q3 2019 in Review

Stonebridge Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q3 2019, closing a stake of 8,950 shares — an estimated $239K sold.

Stonebridge Capital Management first reported a position in ACAD in Q4 2014 and held it in 10 quarters. The position peaked at $675K in Q1 2016. 231 funds tracked by Wall St. Rank hold ACAD as of Q3 2019.

Stonebridge Capital Management reported no remaining Acadia Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Stonebridge Capital Management sold 8,950 Acadia Pharmaceuticals shares in Q3 2019, an estimated $239K.
Stonebridge Capital Management first reported a position in Acadia Pharmaceuticals in Q4 2014 and held it in 10 quarters.
Stonebridge Capital Management's Acadia Pharmaceuticals position peaked at $675K in Q1 2016.
231 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2019.

Based on Stonebridge Capital Management's 13F filing for Q3 2019, filed 2 Oct 2019.